A Phase I/IIa Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVII in Healthy Adult Volunteers
Latest Information Update: 10 Mar 2025
At a glance
- Drugs EG-COVID (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors EyeGene
- 07 Mar 2025 Status changed from recruiting to completed.
- 30 Oct 2023 New trial record